Patients on natalizumab had ganglion cell thinning no different than healthy controls.
Retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) thinning can be identified by optical coherence tomography. Thinning of the RNFL and GCL is caused by a combination of inflammatory activity and degeneration. Investigators evaluated the impact of RNFL thinning during follow-up of at least 1 year, and typically more than 2 years, in 157 patients with multiple sclerosis (MS). Data were analyzed starting after the first year of treatment.
The rate of GCL thinning in 47 healthy controls was 0.1 microns/year. GCL thickness decreased 0.2 microns/year with natalizumab, 0.3 microns/year with intramuscular interferon, 0.3 microns/year with glatiramer acetate, and 0.5 microns/year with subcutaneous interferon. RNFL thinning did not vary a…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)